TWi Biotechnology, Inc.
Taipei Exchange 6610.TWO
TWi Biotechnology, Inc. Net Income for the year ending December 31, 2023: USD -5.56 M
-
TWi Biotechnology, Inc. Net Income for the year ending December 31, 2022 was USD -2.48 M, a -350.32% change year over year.
-
TWi Biotechnology, Inc. Net Income for the year ending December 31, 2021 was USD -551.82 K, a 84.76% change year over year.
-
TWi Biotechnology, Inc. Net Income for the year ending December 31, 2020 was USD -3.62 M, a 2.87% change year over year.
-
TWi Biotechnology, Inc. Net Income for the year ending December 31, 2019 was USD -3.73 M.
| Date | Net Income | EPS (Diluted) | Shares (Diluted, Weighted) | Net Income Margin |
|---|
| CEO | Ms. Yijun Wu |
| IPO Date | Dec. 27, 2016 |
| Location | |
| Headquarters | No. 41, Lane 221 |
| Employees | 21 |
| Sector | Health Care |
| Industries | |
TWi Biotechnology, Inc., a clinical-stage biopharmaceutical company, develops and sells drugs for innate immunity-related diseases in Taiwan. The company development pipeline comprises AC-203, which is in Phase 2 clinical trial for various indications, including epidermolysis bullosa simplex, epidermolysis bullosa, arthritis, gout, and diabetes mellitus; and AC- 1101, which is in Phase 1 trial for the treatment of vitiligo and preclinical stage for the treatment of atopic dermatitis, as well as granuloma annulare and rare autoimmune skin diseases. It has a drug development agreement with Hong Kong Winhealth Pharma Group Co., Limited. in Mainland China, Hong Kong, and Macao markets. TWi Biotechnology, Inc. was founded in 2010 and is based in Taipei, Taiwan.
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email